Literature DB >> 27002537

Verification of the Inactivation of Melanocytic Nevus in vitro Using a Newly Developed Portable High Hydrostatic Pressure Device.

Naoki Morimoto1, Chizuru Jinno, Atsushi Mahara, Natsuko Kakudo, Toshia Fujisato, Kenji Kusumoto, Shigehiko Suzuki, Tetsuji Yamaoka.   

Abstract

High hydrostatic pressure (HHP) technology is a physical method for inactivating tissue. We reported that nevus specimens were inactivated after HHP at 200 MPa and that the inactivated nevus could be used as autologous dermis for covering skin defects. In this study, we verified the inactivation of nevus specimens using a newly developed portable HHP device which will be used in a clinical trial. Nevus tissue specimens were obtained from 5 patients (mean age 7.2 years, range 1-19). We cultured fibroblasts and nevus cells from the tissue specimens and then evaluated their inactivation after HHP at 200 MPa by confirming the attachment of the suspensions and by the live/dead staining of the suspensions, through the dissociation of the cells on chamber slides and by the live/dead staining of the remaining cells. The cells were also quantitatively evaluated by WST-8 assay. We then confirmed the inactivation of the nevus specimens after HHP using explant culture. Our results indicated that fibroblasts and nevus cells were inactivated after HHP at 200 MPa, with the exception of a small percentage of green-colored cells, which reflected the remaining activity of the cellular esterases after HHP. No cells migrated from the nevus specimens after HHP at 200 MPa. We verified the inactivation of fibroblasts and nevus cells cultured from nevus specimens, and in the nevus samples themselves after pressurization at 200 MPa using this device. This device could be used in clinical trials for giant congenital melanocytic nevi and may thus become useful in various medical fields.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27002537     DOI: 10.1159/000444048

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  6 in total

1.  Basolateral pressure challenges mammary epithelial cell monolayer integrity, in vitro.

Authors:  Katharina S Mießler; Constanze Vitzthum; Alexander G Markov; Salah Amasheh
Journal:  Cytotechnology       Date:  2017-08-29       Impact factor: 2.058

2.  Melanin pigments in the melanocytic nevus regress spontaneously after inactivation by high hydrostatic pressure.

Authors:  Michiharu Sakamoto; Naoki Morimoto; Chizuru Jinno; Atsushi Mahara; Shuichi Ogino; Shigehiko Suzuki; Kenji Kusumoto; Tetsuji Yamaoka
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

3.  The sustained release of basic fibroblast growth factor accelerates angiogenesis and the engraftment of the inactivated dermis by high hydrostatic pressure.

Authors:  Tien Minh Le; Naoki Morimoto; Toshihito Mitsui; Sharon Claudia Notodihardjo; Maria Chiara Munisso; Natsuko Kakudo; Kenji Kusumoto
Journal:  PLoS One       Date:  2019-02-21       Impact factor: 3.240

4.  Inactivated Nevus Tissue with High Hydrostatic Pressure Treatment Used as a Dermal Substitute after a 28-Day Cryopreservation Period.

Authors:  Yoshitaka Matsuura; Michiharu Sakamoto; Shuichi Ogino; Jun Arata; Naoki Morimoto
Journal:  Biomed Res Int       Date:  2021-02-24       Impact factor: 3.411

5.  An Exploratory Clinical Trial of a Novel Treatment for Giant Congenital Melanocytic Nevi Combining Inactivated Autologous Nevus Tissue by High Hydrostatic Pressure and a Cultured Epidermal Autograft: Study Protocol.

Authors:  Naoki Morimoto; Chizuru Jinno; Michiharu Sakamoto; Natsuko Kakudo; Tetsuji Yamaoka; Kenji Kusumoto
Journal:  JMIR Res Protoc       Date:  2016-08-11

6.  High Hydrostatic Pressure Therapy Annihilates Squamous Cell Carcinoma in a Murine Model.

Authors:  Toshihito Mitsui; Naoki Morimoto; Atsushi Mahara; Sharon Claudia Notodihardjo; Tien Minh Le; Maria Chiara Munisso; Natsuko Kakudo; Tetsuji Yamaoka; Kenji Kusumoto
Journal:  Biomed Res Int       Date:  2020-03-07       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.